How to Audit Your Audit Risks and Legal Exposure Management Process Before Inspectors Do

The pharmaceutical industry operates in a highly regulated environment, wherein compliance with various regulations pertaining to controlled substances is essential. An effective audit of audit risks and legal exposure management processes not only ensures compliance but also safeguards against potential legal repercussions and ensures that a company is inspection-ready, thereby enhancing organizational efficiency. This article aims to provide a comprehensive understanding of the relevant regulations and guidelines governing audit risks and legal exposure management, covering the expectations of regulatory agencies such as the FDA, EMA, and MHRA.

Regulatory Context

Controlled substances are drugs that have the potential for abuse, and their handling is strictly regulated under several regulations worldwide. In the United States, the Controlled Substances Act (CSA) governs the manufacture, distribution, and dispensing of these substances (21 U.S.C. § 801 et seq.). In the EU, regulations cover similar aspects, outlined under the Directive 2001/83/EC, which establishes a framework for medicinal products, including controlled substances. The UK’s Misuse of Drugs Act 1971 similarly delineates the legal classification and management of these substances.

Regulatory Affairs (RA) professionals play a vital role in maintaining compliance with these regulations, overseeing documentation, and facilitating communication between departments such as Chemistry, Manufacturing and Controls (CMC), Clinical, Pharmacovigilance (PV), Quality Assurance (QA), and Commercial teams.

Legal/Regulatory Basis

Understanding the legal foundation is crucial for any regulatory oversight. In the US, the FDA categorizes controlled substances into schedules (I to V) based on their potential for abuse, accepted medical use, and safety. Schedule I substances are considered the most restricted and include drugs like heroin and LSD. In contrast, Schedule II substances, such as morphine and oxycodone, have recognized medical use but also high potential for abuse.

In the EU, similar categorization exists under the EMA, wherein controlled substances are regulated under the European Regulation (EC) No. 726/2004 and Directive 2001/83/EC. The UK mirrors these regulations through its own legal frameworks, ensuring that anyone dealing with these substances is fully compliant with legislative requirements.

Documentation

Robust documentation is a cornerstone of compliance related to audit risks and legal exposure management. The following key documents should be meticulously maintained:

• Drug Master Files (DMFs): Essential for detailing the production and control of active pharmaceutical ingredients (APIs) used in controlled substances.
• Batch Records: Documentation of each batch’s production, including adherence to Good Manufacturing Practices (GMP).
• Controlled Substance Logs: These logs must detail every transaction involving controlled substances, providing transparency and traceability.
• Audit Reports: Internal audit reports should document compliance, non-compliance, and corrective actions taken. They are critical for demonstrating an organization’s commitment to compliance during regulatory inspections.

Review/Approval Flow

The review and approval process for submissions involving controlled substances is multilayered, involving various stakeholders within a pharmaceutical organization. The following steps typically outline this process:

1. Submission Preparation: The RA team collaborates with CMC and Clinical departments to prepare submission documents, ensuring all necessary data is included, particularly bridging data when applicable.
2. Internal Review: Documents undergo a rigorous internal review involving cross-functional teams to verify consistency and compliance with legal requirements.
3. Submission to Regulatory Authorities: Upon approval of documentation, the RA team submits applications to the appropriate regulatory bodies (e.g., FDA, EMA, MHRA) for review.
4. Regulatory Authority Review: Regulators evaluate submissions, and may issue requests for additional information or clarification (known as ‘Information Requests’ or IRs).
5. Final Approval/Response: After addressing any IRs, approval is granted or further action is required, with timelines varying across different jurisdictions.

Common Deficiencies

A thorough understanding of potential deficiencies can enhance compliance strategies. Common issues identified during inspections include:

• Inaccurate Documentation: Any discrepancies in controlled substance logs or batch records can lead to serious compliance failures.
• Lack of Training Records: Insufficient evidence of staff training on handling controlled substances can be a significant regulatory shortcoming.
• Inadequate Internal Audits: Failure to regularly conduct internal audits or insufficient documentation of corrective actions may be flagged during inspections.
• Non-compliance with Shipping Standards: Not adhering to specific shipping and handling requirements for controlled substances leads to regulatory liabilities.

RA-Specific Decision Points

Regulatory Affairs professionals must be well-versed in key decision points that could impact the submission strategy when dealing with controlled substances. Here are critical considerations:

Filing as Variation vs. New Application

Determining whether to file a variation or a new application is essential for regulatory strategy:

• Variation: Intended for amendments that do not significantly change the quality, safety, or efficacy. Examples include changes in manufacturing site or minor formulation adjustments.
• New Application: Required when there is significant alteration in drug profile, introduction of new therapeutic claims, or complete rebranding.

Justifying Bridging Data

When submitting data from different studies or product formulations, justifying bridging data is vital:

• Rationale: Provide a scientific and regulatory basis for how the data relates to the controlled substance used in the application.
• Comparative Analysis: Include analyses showing similarity and differences between datasets to establish adequate justification.
• Regulatory Precedent: Reference prior approvals or regulatory guidance that supports the use of bridging data.

Practical Tips for Compliance

Ensuring compliance goes beyond understanding regulations; it requires practical implementation. Below are tips to enhance compliance related to audit risks and legal exposure management:

• Regular Training: Ensure all employees that handle controlled substances undergo regular training sessions to stay updated on compliance requirements.
• Sophisticated Tracking Systems: Utilize advanced electronic systems for maintaining logs to minimize human error and streamline data retrieval.
• Mock Audits: Conduct regular audits simulating regulatory inspections to identify potential deficiencies before official reviews.
• Trend Analysis: Keep track of findings from internal audits and agency inspections to address recurring deficiencies proactively.

Agency Questions and Preparing Responses

Agency interactions are a critical part of the compliance landscape. Preparing for common inquiries can smooth communication with regulators:

• Clarification of Changes: Be prepared to explain the rationale and specific changes made in applications, especially in the context of controlled substances.
• Data Integrity Queries: Ensure that all data presented can be easily verified and is supported by documentation that reflects integrity checks.
• Supply Chain Questions: Be ready to provide detailed information about the supply chain for controlled substances, demonstrating that all parties comply with relevant regulations.

Conclusion

An effective audit risk and legal exposure management process ensures not only compliance but also enhances operational readiness for inspections by regulatory agencies. By understanding the regulatory context, maintaining robust documentation, adhering to regulatory standards, and preparing for agency interactions, pharmaceutical companies can safeguard their organizations against legal exposure and approval delays. Ensuring that all stakeholders are equipped with the necessary tools and insights will lay the groundwork for a proactive compliance culture, ultimately enhancing the lifecycle management of controlled substances.

For additional guidance on navigating these regulations, professionals may refer to the FDA’s guidance documents and the EMA’s official website.